Molecular Docking on Azepine Derivatives as Potential Inhibitors for H1N1-A Computational Approach by Frimayanti, N. (Neni) et al.
Proceeding of The 1st  International Conference on Computer Science and Engineering 2014|111 
 
      
Molecular Docking on Azepine Derivatives as 
Potential Inhibitors for H1N1-A Computational 
Approach 
 
Neni Frimayanti1, Marzieh Yaeghoobi2, Fri Murdiya3, Rossi Passarella4 
1 Greenport Takayama Apartment room 301, 2-2-8 Fushimidai Kanazawa Ishikawa 921-8177 Japan 
2 Department of Chemistry Faculty of Science University of Malaya Kuala Lumpur Malaysia 
3 Department of Electrical engineering Faculty of Engineering Riau University 
4Department of Computer Engineering, Faculty of Computer Science, Sriwijaya University 
1nenifrimayanti@gmail.com 
 
Abstract—Azepine are an important class of organic compounds. 
They are effective in a wide range of biological activity such as 
antifeedants, antidepressants, CNS stimulants, calcium channel 
blocker, antimicrobial and antifungal properties. In our continue 
efforts to search for a potent inhibitor for H1N1 virus using 
molecular docking. In this study, 15 azepine (ligands) derivatives 
were docked to the neuraminidase of A/Breving Mission/1/1918 
H1N1 strain in complex with zanamivir (protein). The Cdocker 
energy was then calculated for these complexes (protein-ligand). 
Based on the calculation, the lowest Cdocker interaction energy 
was selected and potential inhibitors can be identified. 
Compounds MA4, MA7, MA8, MA10, MA11 and MA12 with 
promising Cdocker energy was expected to be very effective 
against the neuraminidase H1N1. 
Keywords— molecular docking, azepine derivative, H1N1, 
computational 
I. INTRODUCTION 
Azepine are well established in pharmacological and 
medicinal chemistry. However, limited number of studies had 
been carried out on the synthesis and structure activity 
relationship (SAR) for azepine, especially in terms of anti-
viral activities. The anti-viral effects of benzodiazepines and 
benzothiazepines have mainly been focused on HIV and 
hepatitis viruses. Dibenzothiazepinethione derivatives to have 
anti-viral activities against Varicella-Zoster virus, hepatitis B 
and HIV-1 [1]. In another study, Delpa and co-workers 
showed 1,4- benzothizapines and 1,4-benzodiazepines with a 
peptide side-chain to have inhibitory effect on hepatitis B, and 
D viruses by affecting the binding of the hepatitis virus to 
annexin V [2].  
Our recent interest in azepines has been inspired by the 
anti-viral properties of this class of compounds. Thus, in this 
study we explored on neuraminidase inhibitory activity. To 
the best of our knowledge, there are a limited number of 
reports on the computational approach (i.e. docking) of 
azepine derivative as H1N1 inhibitors. 
 
II. METHODOLOGY 
The docking of these 15 azepine compounds [3] (i.e. 
general molecular structure as presented in Figure 1) onto the 
neuraminidase of A/Breving Mission/1/1918 H1N1 strain in 
complex with zanamivir which downloaded from PDB data 
bank (www.pdb.org, PDB ID: 3B7E) was achieved using 
Discovery studio 2.5 software packages (Accelrys). The 
docking proses were beginning with the preparation of ligand 
and the protein. Hydrogen atoms were added to the protein 
and its backbone was minimized. All ligands were minimized 
before docking.  
 
 
Fig. 1 Molecular structure of benzothiazepine 
 
 
Fig. 2 Xray crystal structure 
Docking was performed through the Cdocker protocol. In 
general, cdocker is a grid based molecular docking method 
that employs CHARMM forcefields. This protein was firstly 
held rigid the ligand were allowed to flex during the 
refinement. Two hundred ligand conformations were then 
generated from the initial ligand structure though high 
temperature molecular dynamic followed by random rotation, 
refinement with grid based (GRID 1) simulated annealing and 
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a final grid based or full force field minimization. Upon 
completion of the docking proses, conformations with the 
lowest cdocker energy were then chosen and compared with 
DANA (active agents against neuramininidase H1N1 with 
Cdocker energy equal to -46.11 kcal/mol). 
III. RESULT AND DISCUSSION 
Docking studies were performed to evaluate the effects of 
agents against neuraminidase. The Cdocker energy reflects the 
interaction energy for the ligand-protein complex and the 
lower energy means the interaction is more stable. The results 
of Cdocker energy are presented in Table I. 
TABLE I 
CDOCKER ENERGY OF AZEPINE 
No Compounds 
Cdocker energy 
(kcal/mol) 
1 MA1 29.26 
2 MA2 27.82 
3 MA3 32.81 
4 MA4 40.52 
5 MA5 28.85 
6 MA6 28.75 
7 MA7 32.86 
8 MA8 35.34 
9 MA9 25.63 
10 MA10 34.31 
11 MA11 36.23 
12 MA12 39.08 
13 MA13 23.50 
14 MA14 29.75 
15 MA15 23.26 
 
The cdocker energy of MA4, MA7, MA8, MA10, MA11 
and MA12 compounds were relatively close to the active 
agents (DANA). It indicated that those compounds can be 
used as new active compounds against neuramininidase 
H1N1, this observation might be due to the azepine as a 
ligand is binding well to the active site of the protein. 
IV. CONCLUSIONS 
Azepines with promising Cdocker energy (compared to 
DANA with Cdocker interaction energy equal to -46.11 
kcal/mol) were expected to be active against neuraminidase. 
Cdocker energy reflects a logical progression for early stage 
drug discovery that can be used to successfully identify drug 
candidates. Further studies are to do the biological test to 
validate the computational results. 
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